Location : Dublin
Country : United Kingdom
Language : ENG
Start : 2020-01-29
End : 2020-01-31
https://www.btog.org/
Specialities : Pneumonology
Real-world experience of Impower150 regimen for EGFR+ NSCLC
Molecular testing for lung cancer in England
Lung cancer frailty research
Brain metastases in ALK+ NSCLC
NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?
New screening and therapy strategies for SCLC
Frontline ALK+ NSCLC management
Analyzing the National Lung Cancer Audit (NLCA)
Lung cancer: actionable targets
Lung cancer palliation in Scotland
Circulating DNA testing commercially available
Concurrent immunotherapy in SCLC
How to achieve an early and fast lung cancer diagnosis?
Patient feedback: lung cancer nurse specialists
Lung cancer molecular testing in the UK
Checkpoint inhibitor resistance in lung cancer
Lung cancer: the issues around late diagnosis
Access to lung cancer care in the UK: UKLCC report
SPORT study: second primary lung cancer
Lung cancer: helping CNSs help patients
UKLCC: early diagnosis
Diagnosis to end of life care: an evolving journey
The role of BTOG annual meeting
NCRI Lung Cancer Study Group: clinical trials
Lung cancer: how can we stop missing it?
NSCLC: care gaps in England
ECLS: preventing late-stage lung cancer
NLCA: addressing deficiencies in care
Looking to the future of screening programs for lung cancer in the UK
UK excels at molecular testing for lung cancer
Systemic treatment following immunotherapy
UK needs to improve interface of primary/secondary care for cancer
The impact of brain metastasis
Where are we with lung cancer?
ADSCaN trial: testing accelerated radiotherapy in NSCLC
NHS resourcing issues and routes to fixing them
Where is the management of lung cancer moving?
NSCLC: filling the gaps
Resourcing and differing opinions for treating NSCLC with brain mets
Neuroendocrine morphology
Managing ALK+ NSCLC
AI to improve cancer imaging
Radiotherapy: do WBRT/PCI still have a role in NSCLC/SCLC?
EORTC Lung Cancer Group update
The tumor microenvironment: lung cancer
NGS & single-gene testing: lung cancer
Equity of access: NHS molecular diagnostics
Liquid vs tissue biopsy in lung cancer
New agents for EGFR+ NSCLC: osimertinib and beyond
Actionable lung cancer targets
Quitting: is vaping effective for patients?
ALTA-1L: brigatinib vs crizotinib in NSCLC
Prof. Popat: BTOG 2020 hot topics
ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC
Chemoimmunotherapy, the UK & extensive-stage SCLC
NICE osimertinib rejection: UK patients
ALTA-1L: brigatinib vs crizotinib
Importance of occupational therapy for patients in early clinical trials
Lung cancer nursing: best practice
Liquid biopsy testing in lung cancer
Introducing liquid biopsies in lung cancer: critical thinking
Incidence of pneumonitis in patients undergoing immunotherapy
Mesothelioma trials update: CONFIRM, BEAT-meso & MARS2
Denis Talbot: lifetime achievement award winner
Early diagnosis: clinical implications
The vaping-related lung injury epidemic
Dr Rintoul: BTOG 2020 highlights
Painting the lung cancer cell picture
A shifting paradigm: lung cancer
The importance of molecular testing
Chemo-IO, IO-IO, or IO-mono: which is correct for lung cancer?
Whole body MRI the future for lung cancer staging
Late diagnosis of lung cancer in the UK
Management of frontline ALK+ NSCLC: brigatinib vs. Alectinib
Antidrug antibodies against CPIs
Lung cancer screening in the UK
Lung Cancer: post-frontline immunotherapy
Dr Newsom-Davis: BTOG 2020 highlights & priorities
Early Diagnosis Matters: UK Lung Cancer Coalition
Stephen Liu: BTOG highlights
Liquid biopsy: a new era
QoL, exercise & lung cancer
Mesothelioma: MARS2 & MesoTRAP
8ème Rencontre scientifique de l'IPCRG
Conférence ATS 2025
Les 13es Journées Pratiques Respiration Sommeil - JPRS 2025
Lung Science Conference - LSC 2025
29e Congrès de Pneumologie de Langue Française - CPLF 2025